Hep C Drug Trends: Cost Driver In 2014, But “Leveling Off” Coming, CMS Actuaries Say
This article was originally published in RPM Report
Executive Summary
CMS actuaries attribute an increase in health spending in 2014 to the expansion of Medicaid and private health insurance coverage and rapid growth in retail drug spending, particularly for new hep C drugs.
You may also be interested in...
US Retail Drug Spending Growth Slows Substantially In 2016
Retail drug spending rose just 1.3% in 2016, following growth rates of 8.9% and 12.4% in 2015 and 2014, respectively. Moderating trend is reported just ahead of two congressional hearings on drug pricing.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.